Georgia Schilling, MD | Authors

UFT/Leucovorin Plus Weekly Irinotecan in Advanced or Metastatic Colorectal Cancer

October 01, 2000

This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer.